Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia, Biphenotypic, Acute 7Burkitt Lymphoma 6Prostatic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 2Leukemia, Myeloid, Acute 2Down Syndrome 2Stomach Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Prostate Cancer Metastatic 1Pinealoma 1Pancreatitis 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia 1Hodgkin Disease 1

Interventions

fludarabine 7Cyclophosphamide 6fludarabine phosphate 5Melphalan 4thymoglobulin 3Tacrolimus 3Methotrexate 3Cytarabine 3Busulfan 3trametinib 2blinatumomab 2Whole-Body Irradiation 2Transplantation 2Thiotepa 2Specimen Handling 2Sirolimus 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Mesna 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Biopsy 2Azacitidine 2omipalisib 1merphos 1imetelstat 1hydrocortisone hemisuccinate 1Vorinostat 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Juvenile × Hydrocortisone × 1 year × Clear all
NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡